Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).
about
Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineChromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomasPaclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity.Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk predictionHigh-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancerChromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification.Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.Positive response to neoadjuvant cyclophosphamide and doxorubicin in topoisomerase II nonamplified/HER2/neu negative/polysomy 17 absent breast cancer patientsAre current development programs realising the full potential of new agents?Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic CoAlteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.The Pathological Response to Anthracycline is Associated with Topoisomerase IIα Gene Amplification in the HER2 Breast Cancer SubsetQuantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.Multiplication of Chromosome 17 Centromere Is Associated with Prognosis in Patients with Invasive Breast Cancers Exhibiting Normal HER2 and TOP2A Status.Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trialKi-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical reviewChromosome instability and benefit from adjuvant anthracyclines in breast cancer.Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group StudyLow expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.Biomarkers in Breast Cancer - An UpdateAdjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trialsTopoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trialsCEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D.A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trialAssociation of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.DNA amplifications in breast cancer: genotypic-phenotypic correlations.Emerging biomarkers in breast cancer care.Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer?Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?Predictive biomarkers in breast cancer: their value in neoadjuvant chemotherapy.The role of anthracyclines in the treatment of early breast cancer.Optimal adjuvant chemotherapy in breast cancer: selection of agents.TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients.Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy.TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.Quantitative prediction of tumor response to neoadjuvant chemotherapy in breast cancer: novel marker genes and prediction model using the expression levels.
P2860
Q26853619-28FECFF4-D148-476A-96E4-743C7037EF04Q26865068-2592FC8A-8375-4E16-921A-04B79470AA5DQ33407805-FF6B4BE4-9177-4A6D-BCBA-FF8B636850D8Q33643786-4E5F81BA-B6DB-42CC-A253-433F1547AF75Q33847811-5E7C2646-5BA5-4902-9D2C-977F8B6E615BQ34048024-605E9268-C04A-4A90-8F5F-BF39FA426562Q34361300-D103456B-1056-48C8-B4DF-F7911913864CQ34417532-1A76E94F-15F3-4D08-B173-185468EDD57FQ34417986-829AB4B4-6F71-414B-B4BC-9D685C63CA38Q34423576-C5DA6BC3-BF69-4B8B-B912-ACD5C4113FC8Q34640536-E5F0019F-1188-4289-AE3E-80C98EDEA455Q34743488-4AB46F0E-EA02-423A-ADBA-07F803A06066Q35021644-0DA1DB36-73DC-4071-ACCB-BD02855CC381Q35029573-E63A4532-31C1-4DC4-8926-BBE130DD3752Q35744973-F0166A17-F1ED-4F54-B365-6ABC101AB10AQ35866923-4FDE9D8A-BC3A-46B7-955B-251F662567DDQ35889568-BA205B0C-AC68-4975-BD55-9900A284F6A5Q35904441-DFA23887-4A92-4E1F-BC68-26691C563F92Q36075278-D909E42C-3C0B-41A9-8783-D39A672D6B51Q36151341-8E61D5AD-490E-425E-AC7C-61D6DDF9DADBQ36245541-E8DE1221-A407-43A0-AAAD-F31E722CBF61Q36295142-07C07B84-6B7E-4A1A-A439-96D1281D53CCQ36387794-C9E8FAB2-991F-482F-B7E7-D8008F3BB93EQ36402262-05DC5006-840D-4BFF-9A79-85F74F89F9ADQ36544667-41F30DB0-D570-45E6-AF57-F2C17A004697Q37040549-277B41BF-B0D2-4B8F-B6EB-FAA3C119844EQ37580175-ADF1BF01-3FBC-41E4-AA4D-527F4467CF4CQ37638287-A1DB4933-CBC2-4793-AD15-029FBDDE82E1Q37763102-49482E88-6D1C-448E-8520-D9E79EDC4526Q37779305-4662B974-65A2-4F4C-A738-E1510851FAACQ37822734-402AD2DB-650E-4D84-BF90-EC80A304A8A0Q37989074-925BAEF4-C1E7-4BEB-955B-BD7AE8DE552BQ38047337-25339992-BEC6-4460-B145-8B3BC2C2DBE4Q38207452-91A5CF18-7F59-4A16-B946-AC7E87EA6390Q38235713-F7953FDC-EF74-4B05-A179-ED31B0D5C63AQ38406512-C089E8D1-C0B2-4C13-BEE7-B4C3D73C57BFQ38414983-455E8912-1505-439F-8E2A-32B281B9A007Q38699879-D0A0DC27-A265-48BE-AFDA-5271D4CAD547Q39336778-26D1A8FA-D3E4-4187-A27C-CDA4B074F04AQ39570743-47655382-D252-4EF8-BE02-51B5F60455E4
P2860
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Predictive markers of anthracy ...... Adjuvant Trial (NEAT/BR9601).
@en
type
label
Predictive markers of anthracy ...... Adjuvant Trial (NEAT/BR9601).
@en
prefLabel
Predictive markers of anthracy ...... Adjuvant Trial (NEAT/BR9601).
@en
P2093
P50
P1433
P1476
Predictive markers of anthracy ...... Adjuvant Trial (NEAT/BR9601).
@en
P2093
Alison F Munro
Chris J Twelves
Christopher J Poole
Christopher McConkey
Daniel W Rea
David A Cameron
Elena Provenzano
Fiona M Campbell
Jeremy Thomas
John M S Bartlett
P304
P356
10.1016/S1470-2045(10)70006-1
P577
2010-01-13T00:00:00Z